Navidea Biopharmaceuticals Inc. recently announced that SpePharm AG has launched Lymphoseek in the Denmark, the Netherlands and the United Kingdom.
SpePharm paid Navidea an upfront payment to commercialize the drug and will also deliver milestone payments and royalties on all European net sales. The deal between the companies covers potential sales in all 28 member states of the European Economic Union.
Lymphoseek was designed to help treat patients with Tis, Tx or T1-T4cN0 breast cancer and T1-T4cN0 melanoma. The drug targets lymph nodes, the most likely place for cancer cells to spread from a primary tumor.
“The commercial launch of tilmanocept is an important revenue provider for Navidea through royalties that boost our ability to progress our Manocept platform further not only in diagnostic utility but also advancing therapeutics development,” Dr. Michael Goldberg, president and chief executive officer of Navidea, said in a statement. “I applaud Norgine in launching tilmanocept’s successful commercialization in three European countries. We also look forward to bringing additional value to our shareholders, and to patients, as Norgine strategizes expanding its commercial launch into the remaining European Union countries.”
Alerts Sign-up